🇺🇸 FDA
Patent

US 9161995

Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (CFTR) gene

granted A61KA61K38/00A61K48/00

Quick answer

US patent 9161995 (Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (CFTR) gene) held by Sangamo Biosciences, Inc. expires Mon Oct 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sangamo Biosciences, Inc.
Grant date
Tue Oct 20 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K38/00, A61K48/00, A61K48/005, A61P